UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144

Benzinga Newsdesk www.benzinga.com Neutral 87.5%

Neg 0% Neu 87.5% Pos 0%

UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.